Download Licensed indications – alternative products to tinzaparin

Licensed indications –alternative products to tinzaparin (Katherine Le Bosquet MI Guy’s and St Thomas’ NHS Foundation Trust
Alternative heparin products and fondaparinux (licensed indications only)
licensed indications:
Low molecular weight heparins
(LMWH)
Tinzaparin
Dalteparin
Enoxaparin
Sodium
sodium
sodium
(Innohep®)
(Fragmin®)
(Clexane®)
Unfractionated heparin (UFH)
Non-proprietary (please see note below)
Fondaparinux
(Arixtra®)
Prophylaxis of thromboembolic
disorders of venous origin, in
particular those which may be
associated with orthopaedic or
general surgery





The treatment of venous
thromboembolic disease presenting
with deep vein thrombosis,
pulmonary embolism or both





The prevention of thrombus
formation in the extracorporeal
circulation during haemodialysis





The treatment of unstable angina
and non-ST-segment-elevation
myocardial infarction





Prophylaxis of venous
thromboembolism in medical
patients bedridden due to acute
illness





Prophylaxis against DVT and thrombo-embolic events in
susceptible patients including prophylaxis for surgical
patients monitoring not required
Treatment of thromboembolism (including deep vein
thrombosis and pulmonary embolism) and unstable angina
- continuous IV infusion (requires monitoring; in practice
LMWH is used in preference)
Treatment of thromboembolism (including deep vein
thrombosis and pulmonary embolism) and unstable angina
- continuous IV infusion (requires monitoring; in practice
LMWH is used in preference)
Prophylaxis against DVT and thrombo-embolic events in
susceptible patients [although not specified this would
include prophylaxis for surgical patients and medical
patients] – monitoring not required
[The information in this table has been taken from edition 62 of the BNF (September 2011) and from current SPCs via www.emc.medicines.org.uk
(accessed 3/11/11)]
Note: There are a number of different UFH products on the market; therefore the above presents a summary of the indications for the drug itself rather
than for a specific preparation. In general UFH can be used for all the licensed indications of Tinzaparin; however this does not always follow current
practice (see above).